A Phase 1 study of the dual-function, liver-targeted, small-interfering RNA conjugate, ARO-DIMER-PA, in adults with mixed hyperlipidaemia, has demonstrated reductions in both TG and LDL-C. Among 31 participants randomised to ARO-DIMER-PA 25 mg, 50 mg, 100 mg, 200 mg, 400 mg or placebo, median baseline TG was 170 mg/dL and mean baseline LDL-C was 135 mg/dL.
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
